The sensor records the date and precise time the inhaler is used and automatically transmit it to an app on a patient’s phone or tablet – storing the information for review by doctors.
“Over-the-counter clearance means that Adherium’s Smartinhaler SmartTouch for Symbicort can now be sold directly to consumers in the US, including through pharmacies and online, without the need for the patient to first obtain a prescription,” the company said.
The stock (ASX:ADR) jumped from 12c to 18.5c after the announcement — cooling slightly to 18c by Tuesday’s close.
“We are now well positioned to launch in the US, following successes in Europe and Australia,” chief Arik Anderson told the market.
“We are providing clinically proven monitoring to support patients in adopting their physicians’ guidance into their daily lives, and so close the gap between science and real-world care.”
share
Link copied to clipboard
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
I want the news:
Hear it first
Get the latest Stockhead news delivered free to your inbox.
Thanks! You’re subscribed, Stockhead news is coming your way soon.